|
Biogen gibt Rechte zurück nach schwachen Phase 1/2 Studiendaten
www.fiercebiotech.com/biotech/...ar-gene-therapy-flunks-trial
Zahlen für Q2/19
"The company believes these funds will be sufficient to allow AGTC to generate data from its ongoing clinical programs, to move the pre-clinical optogenetic program in collaboration with Bionic Sight into the clinic and fund the currently planned research and discovery programs into the first half of 2021. The company expects total cash, cash equivalents and investments as of June 30, 2020 to be between $30 and $40 million."
ir.agtc.com/news-releases/...ults-and-business-update-fourth-0
Zahlen für Q3/19
ir.agtc.com/news-releases/...lts-and-business-update-quarter-9
positive Phase 1/2 Studiedaten (XLRP)
ir.agtc.com/news-releases/...x-month-data-its-ongoing-phase-12
Phase 1/2 Daten für AAV-Gentherapie
ir.agtc.com/news-releases/...im-six-month-data-dose-escalation
Offering
ir.agtc.com/news-releases/...osed-public-offering-common-stock
32,5 Mio. $ Offering
ir.agtc.com/news-releases/...0000-public-offering-common-stock
Zahlen für Q4/19
Vor dem Hintergrund der zuletzt positiven Studiendaten scheint die Bewertung von AGTC momentan recht interessant.
ir.agtc.com/node/10226/html
75 Mio. $ Offering
ir.agtc.com/news-releases/...ffering-common-stock-and-warrants
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
49 | Applied Genetic TECH | iwanooze | Vassago | 24.10.22 10:31 |